92 related articles for article (PubMed ID: 2854788)
1. Prolyl derivatives of enalapril as potential angiotensin converting enzyme inhibitors.
Ciabatti R; Tarzia G; Battaglia F; Barone D; Baldoli E
Farmaco Sci; 1988 Dec; 43(12):989-1003. PubMed ID: 2854788
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and angiotensin converting enzyme inhibitory activity of N-carboxymethyldipeptides with omega-(4-piperidyl)alkyl group.
Waga T; Matsui S; Saito S; Watanabe M; Kajiwara Y; Shirota M; Iijima M; Kitabatake K
Arzneimittelforschung; 1990 Apr; 40(4):407-13. PubMed ID: 2162675
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and pharmacological screening of new angiotensin converting enzyme inhibitors.
Gubert S; Braso MA; Sacristán A; Ortiz JA
Farmaco; 1990 Jan; 45(1):59-79. PubMed ID: 2186741
[TBL] [Abstract][Full Text] [Related]
4. Imidazolyl derivatives of enalapril as potential angiotensin converting enzyme inhibitors.
Cecchi R; Ciabatti R; Favara D; Barone D; Baldoli E
Farmaco Sci; 1985 Aug; 40(8):541-54. PubMed ID: 2995119
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin converting enzyme inhibitors: spirapril and related compounds.
Smith EM; Swiss GF; Neustadt BR; McNamara P; Gold EH; Sybertz EJ; Baum T
J Med Chem; 1989 Jul; 32(7):1600-6. PubMed ID: 2544729
[TBL] [Abstract][Full Text] [Related]
6. [Enalapril--an oral angiotensin-converting enzyme inhibitor: its pharmacological properties and clinical use].
Wiecek A; Grzeszczak W
Pol Tyg Lek; 1988 Feb; 43(9):279-83. PubMed ID: 2841654
[No Abstract] [Full Text] [Related]
7. [Synthesis of angiotensin converting enzyme inhibitors containing residues of substituted quinolines and a study of their biological activity].
Filatova MP; Krit NA; Uskova NN; Maksimova EM; Gracheva IN; Reĭssmann Z
Bioorg Khim; 1991 May; 17(5):690-6. PubMed ID: 1662954
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
Sweet CS
Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
[TBL] [Abstract][Full Text] [Related]
9. [Biochemical and physiological activity of new peptide inhibitors of angiotensin-converting enzyme].
Gomazkov OA; Pozdnev VF; Kalinina EV; Komissarova NV; Medvedeva NA; Nesterova MA; Petriĭ OP
Biull Eksp Biol Med; 1996 Sep; 122(9):279-81. PubMed ID: 8974479
[No Abstract] [Full Text] [Related]
10. Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure.
Sweet CS; Gaul SL; Reitz PM; Blaine EH; Ribeiro LT
J Hypertens Suppl; 1983 Oct; 1(1):53-63. PubMed ID: 6100609
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
Krapcho J; Turk C; Cushman DW; Powell JR; DeForrest JM; Spitzmiller ER; Karanewsky DS; Duggan M; Rovnyak G; Schwartz J
J Med Chem; 1988 Jun; 31(6):1148-60. PubMed ID: 2836590
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory activity and protein binding of L-lysine derivatives as angiotensin converting enzyme inhibitors.
Saito S; Matsui S; Watanabe M; Waga T; Kajiwara Y; Shirota M; Iijima M; Kitabatake K; Matsushita Y; Moriguchi I
Arzneimittelforschung; 1990 Oct; 40(10):1078-81. PubMed ID: 1963299
[TBL] [Abstract][Full Text] [Related]
13. [Effect of enalapril on cerebral circulation and its autoregulation in hypertensive rats].
Adzhienko LM; Asiedu DI
Biull Eksp Biol Med; 1999 Jun; 127(6):642-4. PubMed ID: 10445129
[No Abstract] [Full Text] [Related]
14. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.
Sweet CS; Gross DM; Arbegast PT; Gaul SL; Britt PM; Ludden CT; Weitz D; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):558-66. PubMed ID: 6259323
[No Abstract] [Full Text] [Related]
16. Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys.
Sybertz EJ; Baum T; Ahn HS; Desiderio DM; Pula KK; Tedesco R; Washington P; Sabin C; Smith E; Becker F
Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):216-29. PubMed ID: 3036028
[TBL] [Abstract][Full Text] [Related]
17. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and angiotension converting enzyme inhibitory activity of L-lysyl-N-substituted glycine derivatives.
Saito S; Matsui S; Fukushima S; Watanabe M; Waga T; Kajiwara Y; Shirota M; Iijima M; Kitabatake K
Arzneimittelforschung; 1989 Dec; 39(12):1558-61. PubMed ID: 2560371
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and angiotensin converting enzyme inhibitory activity of N-carboxymethyldipeptides with an omega-aminoalkyl group.
Saito S; Matsui S; Watanabe M; Waga T; Kajiwara Y; Shirota M; Iijima M; Kitabatake K
Arzneimittelforschung; 1990 Mar; 40(3):257-60. PubMed ID: 2346534
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of converting enzyme and thromboxane synthetase in a model of progressive renal disease; effects of enalapril and RS-86328 in the rat.
Rosenkranz RP; Hayashi CM
Proc West Pharmacol Soc; 1988; 31():81-5. PubMed ID: 2850566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
